Boston Scientific

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • In 2022, internal neuromodulation dominated the global neuromodulation market.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.

Acarix appoints Aamir Mahmood as new CEO

Retrieved on: 
Thursday, February 1, 2024

STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.

Key Points: 
  • STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.
  • Mr. Mahmood succeeds Acting CEO Fred Colen and previous CEO Helen Ljungdahl Round.
  • "It is with great pleasure that the Board of Acarix announces the appointment of Aamir Mahmood as the new CEO to lead this exciting phase of rapid growth, especially in the US.
  • Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022.

Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System

Retrieved on: 
Wednesday, January 31, 2024

MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.

Key Points: 
  • Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system
    MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System.
  • "The approval of the FARAPULSE PFA System marks an important milestone for the millions of people living with paroxysmal AF and is an incredible opportunity to bring the first PFA system designed and built solely for this type of ablation therapy to physicians in the U.S.," said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific.
  • The FARAPULSE PFA System, however, relies on tissue-selective, non-thermal electric fields to ablate heart tissue and avoid damage to surrounding structures.
  • The company is developing a navigation-enabled version of the FARAWAVE catheter alongside the FARAVIEW™ Software Module and anticipates regulatory approval in 2024.

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Tuesday, January 30, 2024

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70

Key Points: 
  • Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70
    BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.
  • "I am delighted to welcome Lee, an experienced public biotech legal executive, to enGene as we advance the development of EG-70 in our ongoing pivotal-stage LEGEND study in BCG-unresponsive non-muscle invasive bladder cancer," said Jason D. Hanson, Chief Executive Officer of enGene.
  • Mr. Giguere previously served as Chief Legal Officer and Secretary of Obsidian Therapeutics, a clinical-stage cell and gene therapy company.
  • Mr. Giguere commented: "I am thrilled to join enGene as we work to transform the management of bladder cancer, beginning with BCG-unresponsive NMIBC.

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VIA, FGH, AXNX

Retrieved on: 
Thursday, January 25, 2024

If you are a Via shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Via shareholder, click here to learn more about your rights and options .
  • If you are an FG Group shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Optimove Appoints Hila Shabtai Shemesh as VP of Finance

Retrieved on: 
Thursday, January 25, 2024

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Optimove, the first Customer-Led Marketing Platform, announced today the appointment of Hila Shabtai Shemesh as the company's Vice President of Finance.

Key Points: 
  • NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Optimove, the first Customer-Led Marketing Platform, announced today the appointment of Hila Shabtai Shemesh as the company's Vice President of Finance.
  • Before Lumenis, Hila spent a decade in finance and business at Viola Ventures, M&A and valuation deals at KPMG, and product analysis at Procter & Gamble.
  • With her comprehensive skill set and experience encompassing finance, commercial strategy, business development, product management, and marketing, Hila is set to support Optimove as it makes its next stride forward.
  • We are thrilled to have her as a key management team member.”
    "I am excited and honored to join Optimove during such a significant chapter in the company’s journey,” said Hila Shabtai Shemesh.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDC, HARP, CVLY, AXNX

Retrieved on: 
Wednesday, January 24, 2024

Under the terms of the agreement, MDC shareholders are expected to receive $63.00 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, MDC shareholders are expected to receive $63.00 in cash per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, HARP shareholders will receive $23.00 in cash per share they own.
  • Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – GRCL, AXNX, HARP, CVLY

Retrieved on: 
Saturday, January 20, 2024

It is free and there is no cost or obligation to you.

Key Points: 
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.
  • Codorus Valley Bancorp, Inc. (Nasdaq: CVLY ), relating to its proposed sale to Orrstown Financial Services, Inc.
  • Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator

Retrieved on: 
Thursday, January 25, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240125437671/en/
    Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest.
  • (Photo: Business Wire)
    The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs.
  • The company is now well positioned to plan for delivering this lifesaving technology to patients outside the US."
  • The Jewel P-WCD is limited to investigational use only and is not available for sale in the United States.